Literature DB >> 30215770

Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis.

Desmond Y H Yap1, Chun Hay Tam2, Susan Yung1, Sunny Wong2, Colin S O Tang1, Temy M Y Mok3,4, Catherine K Y Yuen3, Maggie K M Ma1, Chak Sing Lau3, Tak Mao Chan1.   

Abstract

BACKGROUND: There is little data on mycophenolic acid (MPA) pharmacokinetics and pharmacogenomics and optimal MPA exposure in lupus nephritis (LN) patients during long-term maintenance.
METHODS: We measured blood MPA levels at 1, 2, 4, 8, 10 and 12-h post-dose (i.e. C1, C2, C4, C8, C10 and C12) in 88 stable LN patients receiving maintenance prednisolone and mycophenolate mofetil, repeated every 6 months. The relationship between MPA exposure and single nucleotide polymorphisms (SNPs) of adenosine triphosphate-binding cassette subfamily C member 2 (ABCC2; rs2273697, rs3740066, rs717620 and rs17222723), organic anion-transporting polypeptides (OATPs; rs7311358 and rs4149117) and uridine diphosphate glucuronosyltransferase (UGT; rs17863762, rs6714486, rs17868320 and rs72551330) was also investigated.
RESULTS: C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively). C12 inversely correlated with hemoglobin, immunoglobulins and leukocyte levels (P < 0.05 for all). Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004). SNP rs2273697 A/G in the ABCC2 gene was associated with lower MPA exposure compared with G/G (1075.9 ± 239.9 versus 1891.5 ± 918.9 mgh/L per g/kg; P = 0.003). SNPs of OATP and UGT were unrelated to MPA level.
CONCLUSION: MPA C12 correlates with the AUC0-12 and is related to renal flare, infection and anemia. SNP rs2273697 A/G is associated with lower MPA exposure.
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  lupus nephritis; mycophenolic acid; pharmacokinetics

Year:  2020        PMID: 30215770     DOI: 10.1093/ndt/gfy284

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Genetic variation of pharmacogenomic VIP variants in the Chinese Li population: an updated research.

Authors:  Shuangyu Yang; Xia Dou; Zhen Wang; Wenjie Zhang; Kefan Ding; Wenting Meng; Haiyue Li; Jianfeng Liu; Yuanwei Liu; Tianbo Jin
Journal:  Mol Genet Genomics       Date:  2022-02-11       Impact factor: 3.291

2.  Pharmacokinetics and pharmacodynamics profiles of enteric-coated mycophenolate sodium in female patients with difficult-to-treat lupus nephritis.

Authors:  Pajaree Chariyavilaskul; Weeraya Phaisal; Wonngarm Kittanamongkolchai; Chutima Rukrung; Sirirat Anutrakulchai; Yingyos Avihingsanon
Journal:  Clin Transl Sci       Date:  2022-05-15       Impact factor: 4.438

3.  Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis.

Authors:  Chenzhu Zhang; Tsz Wai Tam; Mel Km Chau; Cristina Alexandra García Córdoba; Susan Yung; Tak Mao Chan
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

Review 4.  Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.

Authors:  Mario E Alamilla-Sanchez; Miguel A Alcala-Salgado; Cesar D Alonso-Bello; Gandhy T Fonseca-Gonzalez
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-12-11

Review 5.  Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine.

Authors:  Melisa Intan Barliana; Nadiya Nurul Afifah; Riezki Amalia; Laniyati Hamijoyo; Rizky Abdulah
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

6.  Efficacy of High-Dose Mycophenolate Mofetil in Multitarget Therapy for Lupus Nephritis: Two Consecutive Case Reports.

Authors:  Yoshitaka Furuto; Mariko Kawamura; Akio Namikawa; Hiroko Takahashi; Yuko Shibuya
Journal:  Cureus       Date:  2020-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.